Lucinda Bateman

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Lucinda Bateman (Cindy Bateman), MD, is an ME/CFS physician and researcher. She founded and is Chief Medical Officer of the Bateman Horne Center of Excellence for ME/CFS and Fibromyalgia in Salt Lake City, Utah.[1]

Dr. Bateman was one of the authors of the 2011 case definition, International Consensus Criteria,[2] and was one of the experts on the "Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" that was convened for the 2015 Institute of Medicine report.[3]

Suzanne Vernon, PhD, the Research Liaison at Bateman Horne Center of Excellence works closely with Dr. Bateman on ME/CFS and fibromyalgia research.[4]

Awards[edit | edit source]

Boards and committees[edit | edit source]

CFSAC committee[edit | edit source]

Dr. Bateman was a voting member of the Health and Human Services's Chronic Fatigue Syndrome Advisory Committee for the terms 12/01/05 to 12/01/08[6] & 01/03/06 to 01/03/10[7] and was serving the term 12/13/2017 to Sep 2020 when the committee was dissolved by HHS.[8]

Journal editoral board[edit | edit source]

Dr. Bateman serves on the editorial board of the journal, Fatigue: Biomedicine, Health & Behavior.[9]

ME/CFS Common Data Elements (CDE) Project[edit | edit source]

Member of the Pain Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[10]

Advocacy[edit | edit source]

Open letter to The Lancet[edit | edit source]

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Bateman, along with 41 colleagues in the ME/CFS field, signed the second letter.

Editorials[edit | edit source]

Research studies[edit | edit source]

Clinic location[edit | edit source]

The Bateman Horne Center

24 S. 1100 E., Suite 205

Salt Lake City, Utah 84102

[[1]]

Talks and interviews[edit | edit source]

Webinars[edit | edit source]

Science to patients / Wetenschap voor patienten

Solve ME/CFS Initiative


Blog posts[edit | edit source]


Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ https://batemanhornecenter.org/
  2. ↑ Carruthers, Bruce M.; van de Sande, Marjorie I.; De Meirleir, Kenny L.; Klimas, Nancy G.; Broderick, Gordon; Mitchell, Terry; Staines, Donald; Powles, A.C. Peter; Speight, Nigel; Vallings, Rosamund; Bateman, Lucinda; Baumgarten-Austrheim, Barbara; Bell, David; Carlo-Stella, Nicoletta; Chia, John; Darragh, Austin; Jo, Daehyun; Lewis, Donald; Light, Alan; Marshall-Gradisnik, Sonya; Mena, Ismael; Mikovits, Judy; Miwa, Kunihisa; Murovska, Modra; Pall, Martin; Stevens, Staci (August 22, 2011). "Myalgic encephalomyelitis: International Consensus Criteria". Journal of Internal Medicine. 270 (4): 327–338. doi:10.1111/j.1365-2796.2011.02428.x. ISSN 0954-6820. PMC 3427890. PMID 21777306.
  3. ↑ Syndrome, Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue; Populations, Board on the Health of Select; Medicine, Institute of (February 10, 2015). Biographical Sketches of Committee Members, Consultants, and Staff. National Academies Press (US).
  4. ↑ https://batemanhornecenter.org/suzanne-d-vernon-phd/
  5. ↑ "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
  6. ↑ HHS.gov (2006), Nov 20 & 21, 2006 CFSAC Meeting (PDF) (Minutes)
  7. ↑ HHS.gov (2009), May 27 & 28, 2009 CFSAC Meeting (PDF) (Roster)
  8. ↑ https://www.hhs.gov/ash/advisory-committees/cfsac/about-cfsac/roster/index.html
  9. ↑ "Fatigue: Biomedicine, Health & Behavior". tandfonline.com. Retrieved November 1, 2019.
  10. ↑ "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019.
  11. ↑ Friedman, Kenneth; Bateman, Lucinda; Bested, Alison C.; Nahle, Zaher (August 2019). "Editorial: Advances in ME/CFS Research and Clinical Care". Frontiers in Pediatrics. doi:10.3389/fped.2019.00370.
  12. ↑ Fennell, P. A., & Bateman, L. (2005). "A team approach to treating CFS: Matching best medical practices to phases of illness." CFS Research Review, Summer.
  13. ↑ White, A.T., Light, A.R., Hughen, R.W., Bateman, L., Martins, T.B., Hill, H.R., and Light, K.C. (2010) Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology, 47(4):615-24. doi: 10.1111./j.1469-8986.2010.00978.x
  14. ↑ Shin, Clifford H.; Bateman, Lucinda; Schlaberg, Robert; Bunker, Ashley M.; Leonard, Christopher J.; Hughen, Ronald W.; Light, Alan R.; Light, Kathleen C; Singh, Ila R. (July 2011). "Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome". Journal of Virology. 85 (14): 7195–202. doi:10.1128/JVI.00693-11.
  15. ↑ Albright, Frederick; Light, Kathleen; Light, Alan; Bateman, Lucinda; Cannon-Albright, Lisa A (2011), "Evidence for a heritable predisposition to Chronic Fatigue Syndrome", BMC Neurology, 11 (62), doi:10.1186/1471-2377-11-62
  16. ↑ Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
  17. ↑ Alter, Harvey J.; Mikovits, Judy A.; Switzer, William M.; Ruscetti, Francis W.; Lo, Shyh-Ching; Klimas, Nancy; Komaroff, Anthony L.; Montoya, Jose G.; Bateman, Lucinda; Levine, Susan; Peterson, Daniel; Levin, Bruce; Hanson, Maureen R.; Genfi, Afia; Bhat, Meera; Zheng, HaoQiang; Wang, Richard; Li, Bingjie; Hung, Guo-Chiuan; Lee, Li Ling; Sameroff, Stephen; Heneine, Walid; Coffin, John; Hornig, Mady; Lipkin, W. Ian (2012), "A Multicenter Blinded Analysis Indicates No Association between Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and either Xenotropic Murine Leukemia Virus-Related Virus or Polytropic Murine Leukemia Virus", mBio, 3 (5): e00266–12, doi:10.1128/mBio.00266-12
  18. ↑ Light, Alan R; Bateman, Lucinda; Jo, Daehyun; Hughen, RW; Vanhaitsma, TA; White, AT; Light, Kathleen (2012), "Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome", Journal of Internal Medicine, 271 (1): 64-81, doi:10.1111/j.1365-2796.2011.02405.x
  19. ↑ Light, Kathleen C.; Agarwal, Neeraj; Iacob, Eli; White, Andrea T.; Kinney, Anita Y.; VanHaitsma, Timothy A.; Aizad, Hannah; Hughen, Ronald W.; Bateman, Lucinda (December 2013). "Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome". Psychoneuroendocrinology. 38 (12): 2983–2995. doi:10.1016/j.psyneuen.2013.08.008. PMC 3848711. PMID 24054763.
  20. ↑ Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
  21. ↑ Klimas, N.G.; Ironson, G.; Carter, A.; Balbin, E.; Bateman, L.; Felsenstein, D.; Levine, S.; Peterson, D.; Chiu, K.; Allen, A.; Cunningham, K.; Gottschalk, C.G.; Fletcher, M; Hornig, M.; Canning, C.; Komaroff, A.L. (2015), "Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome", Fatigue: Biomedicine, Health & Behavior, 3 (2): 75-96, doi:10.1080/21641846.2015.1023652
  22. ↑ Bateman, L.; Darakjy, S.; Klimas, N.; Peterson, D.; Levine, S.M.; Allen, A.; Carlson, S.A.; Balbin, E.G.; Gottschalk, G.; March, D. (2015), "Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study", Fatigue: Biomedicine, Health & Behavior, 3 (1): 1-15, doi:10.1080/21641846.2014.978109
  23. ↑ Hornig, M; Montoya, JG; Klimas, NG; Levine, SM; Felsenstein, D; Bateman, L; Peterson, DL; Gottschalk, CG; Schultz, AF; Che, X; Eddy, ML; Komaroff, AL; Lipkin, WI (2015). "Distinct plasma immune signatures in ME/CFS are present early in the course of illness". Science Advances. 1 (1). doi:10.1126/sciadv.1400121.
  24. ↑ Baldwin, Nicole L.; Murray, Kristy O.; Garcia, Melissa N.; Bateman, Lucinda (2016), "Treatment of postural orthostatic tachycardia syndrome and management of myalgic encephalomyelitis/chronic fatigue syndrome following suspected West Nile virus infection", Fatigue: Biomedicine, Health & Behavior, 4 (4): 226-236, doi:10.1080/21641846.2016.1247971
  25. ↑ 25.0 25.1 Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
  26. ↑ Nagy-Szakal, Dorottya; Williams, Brent L.; Mishra, Nischay; Che, Xiaoyu; Lee, Bohyun; Bateman, Lucinda; Klimas, Nancy G.; Komaroff, Anthony L.; Levine, Susan; Montoya, Jose G.; Peterson, Daniel L.; Ramanan, Devi; Jain, Komal; Eddy, Meredith L.; Hornig, Mady; Lipkin, W. Ian (2017), "Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome", Microbiome, 5 (44), doi:10.1186/s40168-017-0261-y
  27. ↑ Montoya, Jose G; Anderson, Jill N; Adolphs, Danya L; Bateman, Lucinda; Klimas, Nancy; Levine, Susan M; Garvert, Donn W; Kaiser, Jon D (2018), "KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial" (PDF), International Journal of Clinical and Experimental Medicine, 11 (3): 2890-2900
  28. ↑ Nagy-Szakal, Dorottya; Barupal, Dinesh K.; Lee, Bohyun; Che, Xiaoyu; Williams, Brent L.; Kahn, Ellie J. R.; Ukaigwe, Joy E.; Bateman, Lucinda; Klimas, Nancy G.; Komaroff, Anthony L.; Levine, Susan; Montoya, Jose G.; Peterson, Daniel L.; Levin, Bruce; Hornig, Mady; Fiehn, Oliver; Lipkin, W. Ian (2018), "Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics", Scientific Reports, 8 (1): 10056, doi:10.1038/s41598-018-28477-9
  29. ↑ Proskauer, Charmian; Rowe, Peter C.; Lapp, Charles W.; DeMaria, Alfred Jr; Bateman, Lucinda; Attewell, John R.; Proskauer, Daniel; Kiernicki, David J.; Adebayo, Seyi (2019). "Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning". Frontiers in Pediatrics. 6. doi:10.3389/fped.2018.00412. ISSN 2296-2360. PMID 30671425.
  30. ↑ Friedman, Kenneth; Bateman, Lucinda; Bested, Alison C.; Nahle, Zaher (August 2019). "Editorial: Advances in ME/CFS Research and Clinical Care". Frontiers in Pediatrics. doi:10.3389/fped.2019.00370.
  31. ↑ Sung, Alexander P.; Tang, Jennifer J-J; Guglielmo, Michael J; Smith-Gagen, Julie; Bateman, Lucinda; Redelman, Doug D.; Hudig, Dorothy (December 27, 2019). "Pilot assessment of low NK cell-mediated ADCC and FCGR3A genetics in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Based on inclusion of family members without ME/CFS as controls, low ADCC is unsuitable as a diagnostic biomarker". MedRxIV. doi:10.1101/2019.12.20.19015438.
  32. ↑ Karhan, Ece; Gunter, Courtney L; Ravanmehr, Vida; Horne, Meghan; Kozhaya, Lina; Renzullo, Stephanie; Placek, Lindsey; George, Joshy; Robinson, Peter N; Vernon, Suzanne D.; Bateman, Lucinda; Unutmaz, Derya (December 26, 2019). "Perturbation of effector and regulatory T cell subsets in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". biorxiv. doi:10.1101/2019.12.23.887505.
  33. ↑ Lee, Jihyun; Vernon, Suzanne D.; Jeys, Patricia; Ali, Weam; Campos, Andrea; Unutmaz, Derya; Yellman, Brayden; Bateman, Lucinda (December 2020). "Hemodynamics during the 10-minute NASA Lean Test: evidence of circulatory decompensation in a subset of ME/CFS patients". Journal of Translational Medicine. 18 (1): 314. doi:10.1186/s12967-020-02481-y. ISSN 1479-5876. PMC 7429890. PMID 32799889.
  34. ↑ Bateman, Lucinda; Bested, Alison C.; Bonilla, Hector F.; Chheda, Bela V.; Chu, Lily; Curtin, Jennifer M.; Dempsey, Tania T.; Dimmock, Mary E.; Dowell, Theresa G.; Felsenstein, Donna; Kaufman, David L. (November 1, 2021). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management". Mayo Clinic Proceedings. 96 (11): 2861–2878. doi:10.1016/j.mayocp.2021.07.004. ISSN 0025-6196.
  35. ↑ "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved March 6, 2019.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

Chronic Fatigue Syndrome Advisory Committee (CFSAC) - (sometimes pronounced SIF-SACK) A US government advisory council that met twice per year, covering current topics related to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Meetings usually lasted for two days and the results were presented to the Secretary of Health and Human Services (HHS). After 15 years, on September 5, 2018, CFSAC's charter was not renewed by the Department of HHS, effectively dissolving the committee without notice or warning.

See Chronic fatigue syndrome advisory committee.

flare-up A symptoms flare in ME/CFS is a temporary increase in symptoms, alternatively known as experiencing post-exertional malaise. May be referred to as a "crash" or "collapse".

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.[1][2]

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

blinded trial A clinical trial is blinded if either the participants or the researchers don't know which treatment group they are allocated to until after the results are interpreted. (Learn more: www.nottingham.ac.uk)

chronic fatigue (CF) - Persistent and abnormal fatigue is a symptom, not an illness. It may be caused by depression, multiple sclerosis, fibromyalgia, chronic fatigue syndrome or many other illnesses. The term "chronic fatigue" should never be confused with the disease chronic fatigue syndrome.

See National Institutes of Health.

National Institutes of Health (NIH) - A set of biomedical research institutes operated by the U.S. government, under the auspices of the Department of Health and Human Services.

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS).[3] (Learn more: www.heart.org)

tachycardia An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS). (Learn more: www.heart.org)

microbiome The full collection of microscopic organisms (especially bacteria and fungi) which are present in a particular environment, particularly inside the human body.

Retrieved from "https://me-pedia.org/w/index.php?title=Lucinda_Bateman&oldid=238511"